A B S T R A C T We have used purified, 125I-labeled human transcobalamin II (TC II), saturated with cobalamin (Cbl), to study the uptake process for the TC II-Cbl complex by intact normal cultured human skin fibroblasts. We have also investigated the possibility that a defect in one step of this process underlies that inborn error of Cbl metabolism-designated cbl C-in which mutant cells are unable to retain Cbl intracellularly or convert it to its coenzyme forms. TC II-Cbl binding at 40C reached a plateau after 3-4 hr; 95% of the bound 1251 was releasable with trypsin. Binding of TC II-Cbl at 40C could be inhibited by human and rabbit TC II-Cbl and human TC II devoid of Cbl but not by other Cbl-binding proteins, albumin, or free Cbl. Specific binding reached saturation at =5 ng TC II/ml (0.13 nM) and could be inhibited by ethylene glycol-bis (,8-aminoethyl ether) N,N,N',N'-tetraacetic acid. At 37°C, the TC II-Cbl complex was internalized as shown by a progressive decrease in the trypsin-releasable fraction of bound 125I. After 2 h at 370C, increasing amounts of acid-soluble 1251 were found in the incubation medium indicating that the labeled TC II was being degraded. Chloroquine, an inhibitor of lysosomal proteolysis, prevented this degradation. The binding, internalization, and degradation of TC II-Cbl by cbl C cells was indistinguishable from that by control cells. Our studies provide additional support for the concepts: (a) that the TC I1-Cbl complex binds to a specific cell surface receptor through a site on the TC II; (b) that the interaction between the receptor and TC II is calcium dependent; (c) that the TC II-Cbl is internalized via
INTRODUCTION
Transcobalamin II (TC II)' is the primary cobalamin (Cbl; vitamin B12) transport protein found in the plasma of man and other miammals. It has been shown to facilitate Cbl uptake by a variety of tissues in vivo and by various cell types in vitro (1) (2) (3) . Several different lines of experimentation using radioactive Cbl bound to unlabeled TC II have been employed to study the Cbl uptake process. Cellular uptake studies have suggested that the TC II-Cbl binds to the cell surface before the internalization of the Cbl (4, 5) . A specific receptor for the TC II-Cbl complex in rat liver and human placental membranes has been identified and is assumed to mediate this TC IICbl binding (6, 7) . Based on sub-cellular fractionation studies after intravenous injection of Cbl in rats, Newmark et al. (8) and Pletsch and Coffey (9) proposed that the TC II-Cbl complex then enters the cell via endocytosis and is transiently localized in secondary lysosomes where the TC II'is degraded and the Cbl is released into the cytoplasm. Subsequently, Cbl is converted to its coenzyme forms, adenosylcobalamin and methylcobalamin. Because of a lack of a label on the protein moiety of the TC II-Cbl complex, the evidence for internalization and degradation of the TC II has been indirect, although recent in vivo studies using [57Co]Cbl bound to 125I-labeled TC II (10) have shown that there is initially a coordinate clearance of both labels from rabbit plasma by a variety of tissues and that the TC II is rapidly degraded in this process.
Fibroblasts from patients expressing the cbl C mutation are deficient in the synthesis of both Cbl coenzymes, adenosylcobalamin and methycobalamin (11, 12) . Previous studies have shown that whereas the initial uptake of labeled Cbl bound to TC II appeared to be comparable in cbl C and control cells, the cbl C cells failed to retain Cbl and bind it to an intracellular protein or proteins (13) which probably represent the two Cbl-dependent apoenzymes: methylmalonyl-CoA mutase (methylmalonylCoA CoA-carbonyl-mutase, EC 5.4.99.2) and N 5-methyltetrahydrofolate:homocysteine methyltransferase (5 -methyltetrahydropteroyl -L -glutamate:Lhomocysteine S-methyltransferase, EC 2.1.1.13) (14, 15) . Because these studies did not distinguish between cell surface binding and internalization, they did not exclude the possibility that the underlying defect in the cbl C cells resides in some process mediating the uptake of TC II-Cbl or the sub-cellular distribution of free Cbl.
This paper presents additional studies of the TC II-Cbl uptake process in normal cultured human skin fibroblasts. We have used purified '251-labeled human TC II saturated with Cbl (125I-TC II) to investigate directly the binding, uptake, and site of degradation of the complex. We have also studied cbl C cells to test the hypothesis that a defect in one step of the uptake process could lead to the failure of the mutant cells to retain Cbl and convert it to its coenzyme forms. Chloroquine, ethylene glycol-bis (f3-aminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA), and bovine serum albumin were purchased from Sigma Chemical Co.
METHODS
Human TC II was purified from normal human plasma and labeled with 1251 as described (10, 16 tuCi/nmol).
The unlabeled, purified human and rabbit TC 11 (10) , and granulocyte R-binder (17) were stored at -25°C in 0.75 M NaCl containing 0.05 M potassium-phosphate, pH 7.5.
Cell culture. Six human diploid skin fibroblast lines were used: three from controls (lines 82, 83, 87) and three from cbl C mutants (78, 178, 287). Cells were studied between their 9th and 27th passage in culture, except line 178 which was between passage 28 and 39. Growth medium was Eagle's minimal essential medium supplemented with 1% (vol/vol) nonessential amino acids, 10% (vol/vol) fetal calf serum, and 100 Ag/ml of kanamycin. Stock cultures were maintained at 37°C in 32-oz glass bottles which were tightly capped after being gassed with 5% C02/95% air. For binding and uptake experiments, cells were harvested from confluent monolayers with trypsin and plated onto 100-mm plastic tissue culture dishes at 7.8-8.8 x 105 cells/ dish. The dishes were incubated at 370C in a humidified, 5% C02/95% air atmosphere. Experiments were done on the 4th day after plating when the cells had been confluent for 1 day.
Binding and uptake of TC II. Studies at 4°C were carried out with the dishes on ice in a cold room. The cells were incubated for 15 min in growth medium to bring the temperature to 4°C. The medium was aspirated, the cells were washed twice with 5 ml of cold Dulbecco's phosphatebuffered saline (PBS), and 6 ml of incubation medium was added. The incubation medium was identical to the growth medium except that it contained 10 mM Hepes, pH 7.4, and the '25I-TC II. Fetal calf serum has no detectable TC II as measured by saturation of the serum with [57Co]Cbl and chromatography on Sephadex G-150.2 After incubation, aliquots of medium were assayed for 1251, and the remainder was aspirated. In most experiments, the cells were washed four times with 5 ml PBS at 4°C and then were brought to room temperature. 1 ml of 0.2 N NaOH was added to the dish, and the monolayer was dissolved. The solubilized cells were transferred to a plastic counting tube, and the dish was washed twice using 1 ml of 0.2 N NaOH. After counting 125I in a Packard automatic gamma scintillation counter (Packard Instrument Co., Inc., Downers Grove, Ill.), an aliquot was taken for determination of cell protein by the method of Lowry et al. (18) . In those experiments designed to distinguish cell surface radioactivity from internalized radioactivity, the cells were harvested by adding 1 ml of 0.125% trypsin in Dulbecco's calcium-and magnesium-free PBS after washing. The dishes were incubated at 37°C until the cells were floating. The cell suspension was transferred to a 15-ml plastic conical centrifuge tube, and the dish was washed twice with cold growth medium. The cell suspension was centrifuged at 1,100 g for 5 min at 4°C. The trypsin supemate was removed and counted; the cell pellet was dissolved in 0.2 N NaOH, counted, and then the cell protein determined.
Studies at 37°C were carried out in an identical manner except that the 15-min incubation for temperature equilibration was omitted. A humidified, C02-incubator was used for the incubation. Binding and uptake of TC II are defined as the amount of 1251 associated with the cells at 40 and 37°C, respectively.
Preparation of cell extracts by sonication and Sephadex G-150 chromatography of cell extracts were carried out as described (13) .
Degradation of TC II. After incubation of the 125I-TC II with cells, 1 ml of the medium was transferred to a conical centrifuge tube and 0.25 ml of 50% trichloroacetic acid was added. After incubation for at least 30 min at 4°C, the precipitate was removed by centrifugation at 600 g for 15 min. The supemate was removed and counted; a blank value was determined by incubating medium in dishes without cells under the same conditions. Degradation of TC II is defined as the total amount of acid-soluble 1251 formed in the presence of cells less the amount formed in the absence of cells. The amount of free iodine in the acid-soluble 125I was determined by chloroform extraction according to Goldstein and Brown (19) .
RESULTS
Effect of iodination on TC II function. To determine if the iodination procedure alters or interferes with the function of TC II in our experimental system, we compared the uptake of unlabeled TC II saturated with [57Co]Cbl (TC II-[57Co]Cbl) to that of '25I-labeled TC II also saturated with [57Co]Cbl (125I_ TC II-[57Co]Cbl). Uptake of the 57Co label by control fibroblasts at 370C was followed for 6 h. As shown in Fig. 1 , the uptake of [57Co]Cbl bound to iodinated TC II was -70% of that bound to unlabeled TC II. The uptake of free [57Co]Cbl was -4% of that bound to unlabeled TC II (data not shown). After a 6-h incubation with either the single-or double-labeled TC II, cell extracts were prepared and chromatographed on Sephadex G-150 (Fig. 2) . The elution pattern of the 57Co label was almost identical in both cases. Each showed a major peak of radioactivity which contains the two Cbl-dependent apoenzymes,-3 and minor peaks at the void volume and regions corresponding to TC II and free Cbl. Thus, the iodinated TC II retained its functional role in the delivery of Cbl to the cell for subsequent metabolism and association with the Cbl-dependent apoenzymes even though its uptake 3 unlabeled potential competitors (Fig. 4) We used human apo-TC II, that is, TC II devoid of cobalamin, to investigate the nature of the recognition site on the TC II-Cbl complex. As shown in Fig. 4B , apo-TC II inhibited binding maximally by 77%. Its apparent affinity for the TC II receptor was approximately half that of holo-TC II. This might be due to conformational differences between apo-and holo-TC II, but it could also reflect a reduced stability of apo-TC II to freezing and thawing (21) shown in other cell studies that calcium plays a role in the interaction between the TC II-Cbl complex and the cell surface (4, 7). (Fig. 6) . At 40C, binding of 125I1 TC II to the cells was relatively slow, and no acidsoluble label was found in the medium over the 6-h incubation (Fig. 6B) . At least 95% of the label was releasable by trypsin (Fig. 6A) , suggesting that the association of TC II with the cells at 40C reflects only cell surface binding. At 37°C, on the other hand, the association of labeled TC II with the cells was more rapid, reaching a plateau by 2 h (Fig. 6D ). This association represents both binding to the cell surface and internalization of the TC II, as shown by a rapid and significant decrease in the percentage of label which can be released from the cells by trypsin (Fig. 6C) . Degradation of 1251-TC IL. A second process that occurs at 37°C is cell-mediated degradation of the 125I-TC II. After a lag of m2 h, an increasing amount of acid-soluble material was found in the medium (Fig.  6D) . This acid-soluble 1251 was not extracted into chloroform and was, therefore, probably still bound to amino acids. We interpret the presence of this celldependent acid-soluble material as evidence that the TC II has been taken up by cells and then degraded to amino acids or small peptides which subsequently appear in the medium.
The lysosomotropic agent chloroquine was used to investigate the nature of the cellular degradation of TC II. Chloroquine has been shown to accumulate in lysosomes of cultured cells and to inhibit lysosomal degradative process in vivo (22) . Chloroquine had no effect on the binding of 125I-TC II to cells at 4°C (data not shown). The effect of 50 AM chloroquine on the kinetics of 125I-TC II uptake and degradation is shown in Fig. 7 . Under these conditions virtually no degradation of TC II occurred. Chloroquine had no effect on the initial uptake of TC II by cells. The apparent increase in uptake at later times can be accounted for by the absence of release of 125I-TC II degradation product from chloroquin-treated cells, which appeared heavily vacuolated due to accumulation of lysosomes. These data suggest that TC II is localized within lysosomes after internalization and that its degradation is dependent on lysosomal proteases. take, and degradation of I251-TC II in cbl C lines with that in control cells. As shown in Fig. 8 tissues. Our present data, also, indicate that a process conforming to adsorptive endocytosis (20) is responcontrol and cbl C lines (Fig. 9) . Finally, no dif-sible for internalization of the TC II-Cbl complex, and ference in 125I-TC II uptake and degradation at 37°C its subsequent localization in lysosomes. was found when mutant and control cells were comFrom our data we conclude that it is also within pared (Fig. 10) .
lysosomes that TC II is degraded. We measured TC II degradation by following the appearance of acid-DISCUSS ION soluble 1251 in the medium. Such acid-soluble radioactivity was not found at 4°C or in the absence of The results presented in this paper are consistent with viable cells, and it did not reflect trivial elution of the model shown in Fig. 11 . We have demonstrated iodide from the labeled protein. Rather, acid-soluble that there is a specific receptor for TC II-Cbl on the 125I appeared only after a distinct time lag at 37°C, surface of cultured human skin fibroblasts. This recep-as would be expected if uptake of the TC II-Cbl comtor resembles that found in human placental membrane plex by the cell was a necessary precedent for its preparations (7) in that it exhibits high affinity for degradation. Furthermore, chloroquine, a known inthe TC II-Cbl complex, somewhat reduced affinity for hibitor of lysosomal proteolysis (22) , inhibited TC II apo-TC II, and no affinity for free Cbl. The data pre-degradation markedly. Finally, preliminary experisented by Fiedler-Nagy et al. (6) also suggest that rat ments from our laboratory show that chloroquine also liver membrane preparations have a high affinity bind-inhibits the release of complex.4 All of these results support the contention that TC II is degraded to free amino acids within lysosomes, that these amino acids then leave the lysosome (and appear as 125I-labeled amino acids in experiments like ours) and that such degradation is a necessary precondition for release of Cbl from the lysosome.
The scheme we and others have presented for the binding, uptake, and lysosomal degradation of TC II is similar to the mechanism proposed for the uptake of some other proteins. Ashwell and Morell (25) have demonstrated the existence of an asialoglycoprotein receptor which mediates the internalization and lysosomal catabolism of asialoglycoproteins and the granulocyte Cbl-binding protein (17) by hepatic parenchymal cells. Goldstein and Brown (26) have defined an analogous pathway in their extensive studies of the binding, uptake and degradation of low density lipoprotein by human fibroblasts. Low density lipoprotein uptake is, in another respect, functionally analogous to TC II uptake in that both proteins serve as carriers mediating the delivery of cell nutrients, cholesterol, and Cbl, respectively. Although the low density lipoprotein receptor appears to be under feedback regulation dependent on intracellular cholesterol content, preliminary results from our laboratory indicate that TC II receptor availability is not modulated by prior exposure to TC II or free Cbl and thus may not be involved in a similar regulatory mechanism. 2 The data with respect to the cbl C mutants show that these cells are comparable to control cells in their binding, uptake, and degradation of TC II. This evidence leads us to conclude that the underlying defect in the cbl C cells must reside at some step beyond the receptor-mediated uptake of Cbl. Although the formal possibility remains that the Cbl is not released from lysosomes to the cytoplasm in these cells, this seems unlikely because the lysosomal degradation of TC II is completely normal and because the total Cbl content of cbl C cells is reduced, not increased. We have postulated that cbl C cells lack an intracellular cobalamin-binding protein (13) . Although we now feel that this protein is not a unique binder but rather represents the Cbl-dependent apoenzymes, N 5-methyltetrahydrofolate:homocysteine methyltransferase and methylmalonyl-CoA mutase (14, 15) , the fact remains that these cells lack an intracellular Cbl-binding activity. We are currently investigating the possibility that the cbl C cells have a primary defect in one of the Cbl-dependent apoenzymes whose role in intracellular Cbl metabolism involves binding and cellular retention as well as enzymatic catalysis. Altematively, 4Youngdahl-Turner, P., R. H. Allen, and L. E. Rosenberg. Unpublished observations.
some as yet undefined step in Cbl activation which is necessary for Cbl binding to the above names apoenzymes may be defective in the mutant cells.
